MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...